# ALMS — Alumis Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ALMS  
**Sources:** 14  
**Published:** 2026-10-04  
**Canonical:** https://app.k3vl4r.com/research/deep-research-alms-alumis-inc-catalysts-narrative-risks-5984

---

# Alumis Inc. (NASDAQ: ALMS) — Research Snapshot (as of 2026-10-04)

**Company profile:** Alumis is a clinical-stage biopharmaceutical company (formerly Esker Therapeutics) focused on oral, selective allosteric inhibitors of tyrosine kinase 2 (TYK2) for immune-mediated diseases, headquartered in the United States [[3]](https://www.alumis.com/), [[14]](https://investors.alumis.com/). Its lead candidate is ESK-001 (envudeucitinib), an oral highly selective TYK2 inhibitor being studied in plaque psoriasis, psoriatic arthritis, and systemic lupus erythematosus (SLE); it is also advancing A-005, a CNS-penetrant TYK2 inhibitor [[14]](https://investors.alumis.com/). Note that the market-cap figure (~$956.53M) and the Nov 12 earnings date were provided as background and are largely corroborated below by independent sources [[4]](https://www.marketbeat.com/stocks/NASDAQ/ALMS/earnings/), [[15]](https://www.marketbeat.com/earnings/reports/2026-5-14-alumis-inc-stock/).

## Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-alms-alumis-inc-catalysts-narrative-risks-5984 (free to sign up)._
